Positive News Sentiment NASDAQ:AMPH Amphastar Pharmaceuticals - AMPH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $31.12 +0.21 (+0.68%) (As of 01/26/2023 04:13 PM ET) Add Compare Share Share Today's Range$30.60▼$31.2350-Day Range$27.99▼$30.9152-Week Range$22.07▼$44.46Volume120,200 shsAverage Volume201,171 shsMarket Capitalization$1.50 billionP/E Ratio20.89Dividend YieldN/APrice Target$39.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Amphastar Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside26.2% Upside$39.00 Price TargetShort InterestHealthy4.57% of Float Sold ShortDividend StrengthN/ASustainability-2.21Upright™ Environmental ScoreNews Sentiment1.56Based on 2 Articles This WeekInsider TradingSelling Shares$15,065 Sold Last QuarterProj. Earnings Growth12.95%From $1.39 to $1.57 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.96 out of 5 starsMedical Sector13th out of 1,048 stocksPharmaceutical Preparations Industry4th out of 513 stocks 3.4 Analyst's Opinion Consensus RatingAmphastar Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $39.00, Amphastar Pharmaceuticals has a forecasted upside of 26.2% from its current price of $30.91.Amount of Analyst CoverageAmphastar Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.57% of the float of Amphastar Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmphastar Pharmaceuticals has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Amphastar Pharmaceuticals has recently decreased by 1.16%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAmphastar Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmphastar Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmphastar Pharmaceuticals has received a 46.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Subcutaneous human immunoglobulin", "Procainamide", "Epinephrine", and "Medroxyprogesterone acetate" products. See details.Environmental SustainabilityThe Environmental Impact score for Amphastar Pharmaceuticals is -2.21. Previous Next 3.6 News and Social Media Coverage News SentimentAmphastar Pharmaceuticals has a news sentiment score of 1.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Amphastar Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest2 people have searched for AMPH on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Amphastar Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,065.00 in company stock.Percentage Held by Insiders27.80% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.72% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Amphastar Pharmaceuticals are expected to grow by 12.95% in the coming year, from $1.39 to $1.57 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amphastar Pharmaceuticals is 20.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.39.Price to Earnings Ratio vs. SectorThe P/E ratio of Amphastar Pharmaceuticals is 20.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 95.14.Price to Book Value per Share RatioAmphastar Pharmaceuticals has a P/B Ratio of 3.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amphastar Pharmaceuticals (NASDAQ:AMPH) StockAmphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Read More Receive AMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AMPH Stock News HeadlinesJanuary 24, 2023 | marketwatch.comNaloxone Market 2023-2027: What Opportunities Plays Vital Role in Growth, and Business DevelopmentsJanuary 15, 2023 | marketwatch.comHyaluronidase Market Size [2023-2028] | Industry Share, Growth Factor, Revenue And Trends Outlook ReportJanuary 26, 2023 | Investing Trends (Ad)YIKES! 220 Pounds of Graphite in Each EV Battery?Most don't know that today's EV batteries contain more graphite than any other essential ingredient... more than lithium, copper or aluminum! The megatrend of electrifying vehicles only adds to graphite demand, expected to skyrocket 1,050% by 2030. Investors have been frustrated in their search for a Made In America solution – until now.January 13, 2023 | marketwatch.comAnaphylaxis Epinephrine Market 2023 : Key Product Segments, Application Analysis, and Industry Growth Forecast by 2028January 12, 2023 | marketwatch.comHyaluronidase Market with Profitable Strategic Report Including [90 No. Pages] Analysis of New Trends, Updates, and Forecast to 2028January 8, 2023 | finance.yahoo.comIs Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Latest Stock Performance Being Led By Its Strong Fundamentals?January 7, 2023 | forbes.comAmphastar PharmaceuticlsJanuary 7, 2023 | marketwatch.comNaloxone Market will Perform Impressively In Forecast Period to 2028 | New Report with 92 No PagesJanuary 26, 2023 | Investing Trends (Ad)YIKES! 220 Pounds of Graphite in Each EV Battery?Most don't know that today's EV batteries contain more graphite than any other essential ingredient... more than lithium, copper or aluminum! The megatrend of electrifying vehicles only adds to graphite demand, expected to skyrocket 1,050% by 2030. Investors have been frustrated in their search for a Made In America solution – until now.December 18, 2022 | marketwatch.comHyaluronidase Market Dynamics with Top Players, Gross Margin, Regional Demand, Plans and Demand Status Forecast to 2028December 18, 2022 | marketwatch.comNaloxone Market Evolution Segmentation and Insight of Trends 2023 to 2028 with Top Countries DataDecember 11, 2022 | marketwatch.comNaloxone Market Insight | USD 35069.28 million | Growing CAGR of 4.09% |Report of 98 Pages | Forecast to 2027December 9, 2022 | marketwatch.comNaloxone Market 2023 : Manufacturers Strategies, Share Estimation, Future Demand and Regional Growth Dynamics 2028December 5, 2022 | finance.yahoo.comAmphastar Pharmaceuticals (NASDAQ:AMPH) shareholders have earned a 10% CAGR over the last five yearsNovember 22, 2022 | finanznachrichten.deAmphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare ConferenceNovember 22, 2022 | marketwatch.comNaloxone Market Size 2022 Global Analysis Report by Segmentation, Regions, Company Sales, Revenue, Production Capacity and Forecast to 2026November 22, 2022 | finance.yahoo.comAmphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare ConferenceNovember 14, 2022 | seekingalpha.comAmphastar: Growth Remains IntactNovember 10, 2022 | finance.yahoo.comAmphastar Pharmaceuticals to Present at the 2022 Jefferies London Healthcare ConferenceNovember 2, 2022 | finance.yahoo.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Could Be 50% Below Their Intrinsic Value EstimateOctober 31, 2022 | finance.yahoo.comEarnings Preview: Amphastar Pharmaceuticals (AMPH) Q3 Earnings Expected to DeclineOctober 28, 2022 | finance.yahoo.comAmphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7, 2022October 10, 2022 | finance.yahoo.comSelect Medical (SEM) Plans 3rd Hospital in Central PennsylvaniaOctober 10, 2022 | finance.yahoo.comIs Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year?October 9, 2022 | finance.yahoo.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a favorite amongst institutional investors who own 62%October 6, 2022 | seekingalpha.comAmphastar: A Pharmaceutical Growth StockOctober 6, 2022 | marketwatch.comSodium Nitroprusside API Market 2022 Industry Outlook, Current Status, Supply-Demand, Growth Opportunities and Top Players Analysis 2028See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AMPH Company Calendar Last Earnings11/07/2022Today1/26/2023Next Earnings (Estimated)3/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AMPH CUSIPN/A CIK1297184 Webwww.amphastar.com Phone(909) 980-9484Fax909-980-8296Employees1,761Year FoundedN/APrice Target and Rating Average Stock Price Forecast$39.00 High Stock Price Forecast$44.00 Low Stock Price Forecast$32.00 Forecasted Upside/Downside+25.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$1.49 Trailing P/E Ratio20.89 Forward P/E Ratio22.39 P/E GrowthN/ANet Income$62.12 million Net Margins15.93% Pretax Margin21.02% Return on Equity16.48% Return on Assets11.20% Debt Debt-to-Equity Ratio0.15 Current Ratio3.76 Quick Ratio2.75 Sales & Book Value Annual Sales$437.77 million Price / Sales3.44 Cash Flow$1.94 per share Price / Cash Flow16.08 Book Value$9.31 per share Price / Book3.34Miscellaneous Outstanding Shares48,331,000Free Float34,895,000Market Cap$1.50 billion OptionableOptionable Beta0.71 Key ExecutivesDr. Ziping Luo Ph.D. (Age 73)Chairman, Chief Scientist & COO Comp: $1.34MDr. Yongfeng Zhang Ph.D. (Age 76)Co-Founder, Pres, CEO, Chief Scientific Officer & Director Comp: $1.93MMr. William J. Peters M.B.A. (Age 55)CFO, Exec. VP of Fin., Treasurer & Director Comp: $1.11MMr. Jacob Liawatidewi M.B.A. (Age 49)Exec. VP of Sales, Marketing & Corp. Admin. Center, Corp. Sec. and Director Comp: $773.69kMr. Rong Zhou M.S. (Age 64)Exec. VP of Production Center Comp: $842.77kDan Dischner M.B.A.VP of HR & Corp. CommunicationTony Marrs M.B.A.M.P.H., Sr. VP of Regulatory Affairs & Clinical OperationsMr. Peter Langosh (Age 70)VP of Operational Improvement and VP of Internal Audit More ExecutivesKey CompetitorsDynavax TechnologiesNASDAQ:DVAXDICE TherapeuticsNASDAQ:DICEReata PharmaceuticalsNASDAQ:RETAKeros TherapeuticsNASDAQ:KROSMannKindNASDAQ:MNKDView All CompetitorsInsiders & InstitutionsZiegler Capital Management LLCSold 6,380 shares on 1/24/2023Ownership: 0.057%Louisiana State Employees Retirement SystemSold 400 shares on 1/24/2023Ownership: 0.037%Allspring Global Investments Holdings LLCSold 116,159 shares on 1/23/2023Ownership: 0.228%Veriti Management LLCSold 618 shares on 1/20/2023Ownership: 0.019%Exchange Traded Concepts LLCBought 1,135 shares on 1/18/2023Ownership: 0.077%View All Insider TransactionsView All Institutional Transactions AMPH Stock - Frequently Asked Questions Should I buy or sell Amphastar Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AMPH shares. View AMPH analyst ratings or view top-rated stocks. What is Amphastar Pharmaceuticals' stock price forecast for 2023? 4 analysts have issued 12 month target prices for Amphastar Pharmaceuticals' shares. Their AMPH share price forecasts range from $32.00 to $44.00. On average, they predict the company's stock price to reach $39.00 in the next year. This suggests a possible upside of 26.2% from the stock's current price. View analysts price targets for AMPH or view top-rated stocks among Wall Street analysts. How have AMPH shares performed in 2023? Amphastar Pharmaceuticals' stock was trading at $28.02 at the start of the year. Since then, AMPH shares have increased by 10.3% and is now trading at $30.91. View the best growth stocks for 2023 here. When is Amphastar Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023. View our AMPH earnings forecast. How were Amphastar Pharmaceuticals' earnings last quarter? Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) issued its earnings results on Monday, November, 7th. The company reported $0.32 EPS for the quarter, hitting analysts' consensus estimates of $0.32. The company earned $120.13 million during the quarter, compared to analysts' expectations of $126.20 million. Amphastar Pharmaceuticals had a trailing twelve-month return on equity of 16.48% and a net margin of 15.93%. What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO? 35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend. What other stocks do shareholders of Amphastar Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT). What is Amphastar Pharmaceuticals' stock symbol? Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH." Who are Amphastar Pharmaceuticals' major shareholders? Amphastar Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.36%), Lam Group Inc. (0.27%), Allspring Global Investments Holdings LLC (0.23%), Exchange Traded Concepts LLC (0.08%), Ziegler Capital Management LLC (0.06%) and Yousif Capital Management LLC (0.05%). Insiders that own company stock include David Maris, Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, William J Peters and Yakob Liawatidewi. View institutional ownership trends. How do I buy shares of Amphastar Pharmaceuticals? Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amphastar Pharmaceuticals' stock price today? One share of AMPH stock can currently be purchased for approximately $30.91. How much money does Amphastar Pharmaceuticals make? Amphastar Pharmaceuticals (NASDAQ:AMPH) has a market capitalization of $1.49 billion and generates $437.77 million in revenue each year. The company earns $62.12 million in net income (profit) each year or $1.49 on an earnings per share basis. How many employees does Amphastar Pharmaceuticals have? The company employs 1,761 workers across the globe. How can I contact Amphastar Pharmaceuticals? Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The official website for the company is www.amphastar.com. The company can be reached via phone at (909) 980-9484, via email at jasons@amphastar.com, or via fax at 909-980-8296. This page (NASDAQ:AMPH) was last updated on 1/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.